Pateclizumab, also known as RG 7416 or the drug, represents a promising novel groundbreaking therapeutic approach strategy candidate for treating managing addressing various specific autoimmune inflammatory neurological conditions. This monoclonal antibody The antibody RG 7416 selectively target